Coya Therapeutics announces issuance of new U.S. patent for IL-2

Coya Therapeutics (COYA) announced the issuance of a U.S. patent relevant to its investigational ready-to-use liquid formulation of IL-2. In particular, the U.S. Patent and Trademark Office, USPTO, has granted patent number US 12,312,389 B2, which covers methods of producing highly stable liquid formulations of IL-2. Through an existing agreement, Coya has the exclusive in-vivo rights to this patent and other related intellectual property spanning multiple indications both as monotherapy and combination therapies.